Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

David Sebag-Montefiore, Richard J Stephens, Robert Steele, John Monson, Robert Grieve, Subhash Khanna, Phil Quirke, Jean Couture, Catherine de Metz, Arthur Sun Myint, Eric Bessell, Gareth Griffiths, Lindsay C Thompson, Mahesh Parmar, David Sebag-Montefiore, Richard J Stephens, Robert Steele, John Monson, Robert Grieve, Subhash Khanna, Phil Quirke, Jean Couture, Catherine de Metz, Arthur Sun Myint, Eric Bessell, Gareth Griffiths, Lindsay C Thompson, Mahesh Parmar

Abstract

Background: Preoperative or postoperative radiotherapy reduces the risk of local recurrence in patients with operable rectal cancer. However, improvements in surgery and histopathological assessment mean that the role of radiotherapy needs to be reassessed. We compared short-course preoperative radiotherapy versus initial surgery with selective postoperative chemoradiotherapy.

Methods: We undertook a randomised trial in 80 centres in four countries. 1350 patients with operable adenocarcinoma of the rectum were randomly assigned, by a minimisation procedure, to short-course preoperative radiotherapy (25 Gy in five fractions; n=674) or to initial surgery with selective postoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent 5-fluorouracil) restricted to patients with involvement of the circumferential resection margin (n=676). The primary outcome measure was local recurrence. Analysis was by intention to treat. This study is registered, number ISRCTN 28785842.

Findings: At the time of analysis, which included all participants, 330 patients had died (157 preoperative radiotherapy group vs 173 selective postoperative chemoradiotherapy), and median follow-up of surviving patients was 4 years. 99 patients had developed local recurrence (27 preoperative radiotherapy vs 72 selective postoperative chemoradiotherapy). We noted a reduction of 61% in the relative risk of local recurrence for patients receiving preoperative radiotherapy (hazard ratio [HR] 0.39, 95% CI 0.27-0.58, p<0.0001), and an absolute difference at 3 years of 6.2% (95% CI 5.3-7.1) (4.4% preoperative radiotherapy vs 10.6% selective postoperative chemoradiotherapy). We recorded a relative improvement in disease-free survival of 24% for patients receiving preoperative radiotherapy (HR 0.76, 95% CI 0.62-0.94, p=0.013), and an absolute difference at 3 years of 6.0% (95% CI 5.3-6.8) (77.5%vs 71.5%). Overall survival did not differ between the groups (HR 0.91, 95% CI 0.73-1.13, p=0.40).

Interpretation: Taken with results from other randomised trials, our findings provide convincing and consistent evidence that short-course preoperative radiotherapy is an effective treatment for patients with operable rectal cancer.

Figures

Figure 1
Figure 1
Trial profile CRT=chemoradiotherapy. CRM=circumferential resection margin. ITT=intention to treat.
Figure 2
Figure 2
Proportion of patients with a confirmed local recurrence (A), disease-free survival (B), and overall survival (C)
Figure 3
Figure 3
Summary of reduction in risk of local recurrence in phase III trials that have assessed short-course preoperative radiotherapy with 5 Gy per fraction

References

    1. Holm T, Cedermark B, Rutqvist LE. Local recurrence of rectal adenocarcinoma after ‘curative’ surgery with and without preoperative radiotherapy. Br J Surg. 1994;81:452–455.
    1. Wong CS, Cummings BJ, Brierley JD. Treatment of locally recurrent rectal carcinoma—results and prognostic factors. Int J Radiat Oncol Biol Phys. 1998;40:427–435.
    1. Stockholm Colorectal Cancer Study Group Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol. 1996;3:423–430.
    1. Dahl O, Horn A, Morild I. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway. Cancer. 1990;66:2286–2294.
    1. Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur J Cancer. 1994;30A:1602–1606.
    1. Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer. 1995;75:2269–2275.
    1. Improved survival with preoperative radiotherapy in resectable rectal cancer Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–987.
    1. Medical Research Council Rectal Cancer Working Party Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet. 1996;348:1605–1610.
    1. Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis Colon Rectum. 1994;37:1205–1214.
    1. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13:245–252.
    1. Fisher B, Wolmark N, Rockette H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21–29.
    1. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA. 1988;259:3571–3578.
    1. Medical Research Council Rectal Cancer Working Party Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet. 1996;348:1610–1614.
    1. Krook JE, Moertel CG, Gunderson LL. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–715.
    1. Tveit KM, Guldvog I, Hagen S. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg. 1997;84:1130–1135.
    1. O'Connell MJ, Laurie JA, Kahn M. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300.
    1. NIH consensus conference Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–1450.
    1. Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum. 1998;41:543–549.
    1. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg. 1994;220:676–682.
    1. Marijnen CA, Kapiteijn E, van de Velde CJ. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2002;20:817–825.
    1. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–460.
    1. Enker WE. Total mesorectal excision—the new golden standard of surgery for rectal cancer. Ann Med. 1997;29:127–133.
    1. Adam IJ, Mohamdee MO, Martin IG. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344:707–711.
    1. Quirke P, Steele R, Monson J. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821–828.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
    1. Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer. 1999;35:238–247.
    1. Sebag-Montefiore D, Quirke P, Steele R, Couture J, Thompson L, Stephens R. The impact of short course pre-operative radiotherapy on patients' quality of life: data from the MRC CR07/NCIC-CTG CO16 randomised clinical trial in patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2008;72(suppl 1):S28. (abstr 61).
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646.
    1. Machin D, Cheung YB, Parmar MKB. Survival analysis: a practical approach. 2nd edn. John Wiley and Sons; Chichester: 2006.
    1. Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2007;2 CD002102.
    1. Frykholm GJ, Pahlman L, Glimelius B. Combined chemo and radiotherapy vs radiotherapy alone in the treatment of primary non-resectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys. 2001;50:427–434.
    1. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–5650.
    1. Marijnen CA, van de Velde CJ, Putter H. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847–1858.
    1. Peeters KC, van de Velde CJ, Leer JW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–6206.
    1. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126–6131.
    1. Gerard JP, Conroy T, Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.
    1. Bosset JF, Collette L, Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–1123.
    1. Sauer R, Becker H, Hohenberger W. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.
    1. Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15–24.
    1. Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Long term results of a randomised trial comparing short-course radiotherapy vs preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–1223.
    1. McLachlan S, Fisher R, McLure B. A comparison of quality of life in patients with T3 rectal cancer receiving short course vs long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04) Proc Am Soc Clin Oncol. 2008;26(15S):202s. (abstr 4097).
    1. Mercury Study Group Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132–139.
    1. Mercury Study Group Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel